Novo Nordisk A/S buy BastiBBC
Summary
This prediction ended on 06.03.12 with a price of €21.18. With a performance of 44.30% the BUY prediction by BastiBBC was a big success. BastiBBC has 50% into this predictionNovo Nordisk is a Danish pharmaceutical company that specializes in diabetes care and research. It is considered to be one of the largest companies in the world that focus exclusively on diabetes management, with a product portfolio that ranges from insulin treatment to obesity management. The company is listed on the Copenhagen Stock Exchange and has gained global recognition for its commitment to sustainable business practices and its contribution to diabetes research and treatment. Novo Nordisk has a strong financial track record and has consistently delivered solid returns to investors over the years.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S | - | - | - | - |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% | 16.867% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% | 45.898% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% | 2.760% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% | 42.955% |
Comments by BastiBBC for this prediction
In the thread Novo Nordisk A/S diskutieren
Kaufen
Novo Nordisk ist immer noch eine klarer Kauf. Wenn sich die Märkte erholen, könnte die Aktie über 100 Euro klettern. Das Kursziel sehe ich bei 110 Euro für die nächsten sechs Monate.
Stopped prediction by BastiBBC for Novo Nordisk A/S
Novo Nordisk A/S
06.08.16
06.02.17
06.02.17
Novo Nordisk A/S
17.06.15
17.12.15
17.12.15